XTLB
XTL Biopharmaceuticals Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
XTL Biopharmaceuticals Ltd
Expected move
No implied move.
XTL Biopharmaceuticals Ltd
1.82
+0.06 · +3.41%
post 1.61 −11.54%
No changes.
No changes.
No 13F holders.
No 13F holders.
No peers for XTL Biopharmaceuticals Ltd yet.
No peers for XTL Biopharmaceuticals Ltd yet.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Annual filing, covered
20-F parsed · Jun 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
Management, not covered
Not covered · DEF 14A, 8-K 5.02
13F holdings, not covered
No 13F holders · latest quarter
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Jun 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
Management, not covered
Not covered · DEF 14A, 8-K 5.02
13F holdings, not covered
No 13F holders · latest quarter
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.